Understand · Treat · Recover

Chronic Myeloid Leukemia (CML)

CML is usually driven by BCR::ABL1, a target that modern oral medicines can block. Long-term monitoring remains essential even when symptoms disappear.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 6 of 20 · B · Leukemia

What BCR::ABL1 means

A rearrangement between chromosomes 9 and 22 produces the Philadelphia chromosome and the BCR::ABL1 fusion gene. Its protein sends an abnormal growth signal. This change is usually acquired in blood-forming cells rather than inherited. CML may be discovered on a routine CBC or after fatigue, sweats, weight loss or fullness from an enlarged spleen. Blood and marrow tests establish the diagnosis and disease phase.

Chronic phase and progression

Most people are diagnosed in chronic phase. Blast phase is advanced disease that behaves more like acute leukemia and needs a different approach. Classification systems do not use identical phase definitions; the team should explain which system applies. A very high count alone does not tell the whole story. Response to treatment and the nature of the abnormal cells are important.

Choosing a TKI

Tyrosine kinase inhibitors include imatinib, dasatinib, nilotinib, bosutinib, ponatinib and asciminib in appropriate settings. Selection depends on disease risk, prior treatment, mutation findings, cardiovascular or lung problems, interactions, pregnancy plans and access. Some medicines have specific food requirements. Newer does not automatically mean best for every person. Discuss persistent adverse effects; dose adjustment or a change of drug may be safer than stopping on one’s own.

Molecular monitoring: more than a normal CBC

Quantitative PCR measures BCR::ABL1, usually reported on the International Scale. Tests are commonly performed about every three months early in care, with later timing individualized. The team follows the trend and response milestones, not one isolated fluctuation. Major molecular response generally means BCR::ABL1 at or below 0.1% on this scale. A rising result may prompt a repeat sample, an adherence and interaction review, or mutation testing. A normal blood count cannot substitute for molecular monitoring.

Treatment-free remission

Some people with sustained deep molecular response after prolonged therapy can attempt treatment-free remission under a structured specialist plan. This requires reliable access to frequent high-quality PCR tests and a clear threshold for restarting treatment. Many patients are not eligible, and some need to restart after a molecular recurrence. Do not stop a TKI because a report says “undetectable”: that phrase depends on test sensitivity and sample quality.

Living well and planning ahead

For many patients with well-controlled chronic-phase CML, long-term outcomes are very good. Adherence, molecular follow-up and control of other health problems matter. Keep a record of PCR results, medicines and missed doses. Discuss pregnancy before conception because treatment adjustments require specialist planning. Resistant or advanced CML may require additional drugs or allogeneic transplantation. Ask about affordable quality-assured medicines and laboratory access rather than choosing between tablets and monitoring.

Take-home message

Take treatment consistently and keep PCR appointments; symptom control is not the same as molecular control.

Common questions

Is lifelong treatment always necessary?

Many need long-term treatment. A carefully selected group may attempt supervised treatment-free remission.

Can I stop for side effects or a holiday?

Do not interrupt independently. Contact the team; there may be safer adjustments, supportive treatment or alternatives.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.